RTTNews | Sep 27, 2021 03:04AM EDT

03:04 Monday, September 27, 2021 (RTTNews.com) - Evelo Biosciences, Inc. (EVLO), a clinical stage biotechnology company developing SINTAX medicines, announced Monday positive data from its Phase 2 study evaluating EDP1815 versus placebo for the treatment of mild and moderate psoriasis.

Based on these data, the company said it intends to advance EDP1815 towards registration studies in psoriasis.

The company observed a statistically significant reduction in the Psoriasis Area and Severity Index or PASI score, as measured by the proportion of patients achieving at least 50% improvement in PASI from baseline at the week 16 timepoint.

EDP1815 is an investigational oral biologic currently in development for the treatment of a broad range of inflammatory diseases, including clinical programs in psoriasis, atopic dermatitis, and COVID-19.

EDP1815 was observed to be well tolerated in the Phase 2 study. The safety data were comparable to placebo and consistent with what was previously reported in a Phase 1b study.

In the Phase 2 study, the PASI scores were assessed by both mean changes from baseline and responder rates. The primary endpoint was the mean percentage change in PASI between treatment and placebo and was prespecified as a Bayesian analysis.

The company added that the Bayesian approach provides an estimate of the probability that EDP1815 is superior to placebo. The 16-week primary endpoint gave probabilities that EDP1815 is superior to placebo ranging from 80% to 90% across the prespecified analyses and cohorts.

Read the original article on RTTNews ( https://www.rttnews.com/3228283/evelo-biosciences-announces-positive-phase-2-clinical-data-with-edp1815-in-psoriasis.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved